The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2018 | Individualizing patient care in CML and MPNs
This is an exciting time for chronic myeloid leukemia (CML) and myeloproliferative neoplasms (MPNs), with new treatments on the horizon. Here, Claire Harrison, MD, FRCP, FRCPath, from Guy’s and St Thomas’ NHS Foundation Trust, London, UK, gives an overview of the session she chaired on individualizing care for patients with CML and MPNs at the 2018 British Society for Hematology (BSH) Annual Scientific Meeting in Liverpool, UK. Prof. Harrison touches upon the program, which was designed with an overlap for the two conditions in mind, addressing several of the session speakers, including Adam Mead, who spoke on stem cell dynamics and treatment-free remission in CML, Anna Godfrey, who covered essential thrombocythemia, and John Mascarenhas, who discussed future directions for myelofibrosis.
